ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety

[1]  M. Kołaczkowski,et al.  Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  M. Kołaczkowski,et al.  ADN‐1184 a monoaminergic ligand with 5‐HT6/7 receptor antagonist activity: pharmacological profile and potential therapeutic utility , 2014, British journal of pharmacology.

[3]  H. Bussche,et al.  Impact of safety warnings on antipsychotic prescriptions in dementia: Nothing has changed but the years and the substances , 2013, European Neuropsychopharmacology.

[4]  T. Steimer,et al.  Animal models of anxiety disorders in rats and mice: some conceptual issues , 2011, Dialogues in clinical neuroscience.

[5]  Paul G Shekelle,et al.  Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. , 2011, JAMA.

[6]  Wendy J Mack,et al.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. , 2011, The American journal of psychiatry.

[7]  G. Cheung,et al.  Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials. , 2011, The New Zealand medical journal.

[8]  M. Tsolaki,et al.  A Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and Psychological Symptoms in Dementia (BPSD) , 2011, Neurobiology of Aging.

[9]  Jane B Shofer,et al.  Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[10]  A. Nobili,et al.  Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units , 2009, International clinical psychopharmacology.

[11]  John M. Davis,et al.  Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.

[12]  C. Pedone,et al.  Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) , 2008, Current neuropharmacology.

[13]  A. Wesołowska.  The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors. , 2008, European journal of pharmacology.

[14]  Y. Ohno,et al.  Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. , 2007, European journal of pharmacology.

[15]  A. Wesołowska,et al.  Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression , 2007, Neuropharmacology.

[16]  R. Depoortère,et al.  Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics , 2007, Behavioural pharmacology.

[17]  A. Wesołowska,et al.  Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression , 2006, Neuropharmacology.

[18]  Philip S. Insel,et al.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  Hans-Jürgen Möller,et al.  Antipsychotic and antidepressive effects of second generation antipsychotics , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[20]  H. Möller.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[21]  M. Millan,et al.  The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines , 2003 .

[22]  P. D. De Deyn,et al.  Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. , 2001, The Journal of clinical psychiatry.

[23]  I. McKeith,et al.  Anxiety, depression and psychosis in vascular dementia: prevalence and associations. , 2000, Journal of affective disorders.

[24]  H. Möller.  Definition, Psychopharmacological Basis and Clinical Evaluation of Novel/Atypical Neuroleptics: Methodological Issues and Clinical Consequences , 2000, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[25]  F. Graeff,et al.  Role of 5-HT in stress, anxiety, and depression , 1996, Pharmacology Biochemistry and Behavior.

[26]  C. Broekkamp,et al.  Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. , 1986, European journal of pharmacology.

[27]  S. File,et al.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat , 1986, Pharmacology Biochemistry and Behavior.

[28]  Siegel Rk.  Phencyclidine and ketamine intoxication: a study of four populations of recreational users. , 1978 .

[29]  P. Simon,et al.  Evaluation of a rapid technique for detecting minor tranquilizers. , 1971, Neuropharmacology.

[30]  C. Nemeroff,et al.  Neurobiology of psychiatric disorders , 2012 .

[31]  B. Beer,et al.  A simple and reliable conflict procedure for testing anti-anxiety agents , 2004, Psychopharmacologia.

[32]  K. Brady,et al.  Gabapentin in the treatment of cocaine dependence: a case series. , 2001, The Journal of clinical psychiatry.

[33]  T. Svensson,et al.  Enhancement of antipsychotic-like effects by combined treatment with the α1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats , 2000, Journal of Neural Transmission.

[34]  R. K. Siegel.  Phencyclidine and ketamine intoxication: a study of four populations of recreational users. , 1978, NIDA research monograph.